Interim Clinical Commissioning Policy: IL-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 (adults)

Document first published:
Page updated:
Publication type:

The proposal is: Tocilizumab is recommended to be available as a treatment option through routine commissioning for adult patients (aged 18 years and older) hospitalised with COVID-19 in accordance with the criteria set out in this document.

Patients may alternatively be considered for treatment with sarilumab where tocilizumab is unavailable for this indication or cannot be used.


Published 31 January 2022.